Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Johnson & Johnson Scraps Phase II Study on Antiviral for Dengue Virus
02:01pm, Monday, 07'th Oct 2024
As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.
Top 3 Risk-Averse Stocks to Add Stability to Your Portfolio
08:16am, Monday, 07'th Oct 2024
While some investors relish the thrill of high-growth ventures with the potential for significant returns, others prioritize capital preservation and seek out investments that offer security and stabi
3 Undervalued Dividend Stocks Primed for Growth in 2025
07:02am, Monday, 07'th Oct 2024
In volatile markets, investors are often reminded of the relative security in dividend stocks. These are considered safe havens that can help you generate strong long-term returns.
5 Relatively Secure And Cheap Dividend Stocks To Invest In -- October 2024
09:00am, Saturday, 05'th Oct 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering pr
Buy 2 October Dogs Of The Dow And Watch 5 More
02:38am, Saturday, 05'th Oct 2024
"The Dow® [adds a stock] if the company has an excellent reputation,
Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
04:30pm, Friday, 04'th Oct 2024
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Guggenheim Global Healthcare Conference on Tuesday, November 12th, at the InterContinental Boston in Boston,
Chicago Court Upholds $45 Million Mesothelioma Verdict Against Johnson & Johnson
01:37pm, Friday, 04'th Oct 2024
CHICAGO--(BUSINESS WIRE)--A Circuit Court in Cook County, Ill., has denied a request by Johnson & Johnson (NYSE:JNJ) for a new trial in a mesothelioma lawsuit decided in April, upholding a jury verdic
Johnson & Johnson discontinues dengue drug study
09:19am, Friday, 04'th Oct 2024
Johnson & Johnson said on Friday it will discontinue its mid-stage field study evaluating the efficacy of its antiviral drug candidate for the prevention of dengue.
Stock Picks From Seeking Alpha's September 2024 New Analysts
08:00am, Friday, 04'th Oct 2024
In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and
2 Smart Income Stocks to Buy Right Now
05:20am, Friday, 04'th Oct 2024
These storied companies have a lot to offer different investors.
Why Johnson & Johnson (JNJ) Dipped More Than Broader Market Today
06:51pm, Thursday, 03'rd Oct 2024
Johnson & Johnson (JNJ) concluded the recent trading session at $160.50, signifying a -0.42% move from its prior day's close.
Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA® reduced risk of death by 23 percent at 24 months compared to enzalutamide LISBON, Portugal , Oct. 2, 2024 /PRNewswire/ -- Jo
J&J to invest more than $2 billion in new manufacturing facility
02:08pm, Tuesday, 01'st Oct 2024
Johnson & Johnson said on Tuesday it will invest more than $2 billion to build a new manufacturing facility at Wilson, North Carolina.
AHF: J&J Retreats From Its Scheme to Gut 340B Drug Pricing Program
05:37pm, Monday, 30'th Sep 2024
WASHINGTON--(BUSINESS WIRE)--AHF: J&J Retreats from its Scheme to Gut 340B Drug Pricing Program.
Results from CEPHEUS study highlight DARZALEX FASPRO® quadruplet regimen as a potential standard of care in newly diagnosed patients regardless of transplant eligibility New indication would be the f
